FORM 4

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response: 0.5								

1. Name and Address of Reporting Person* <u>DIXON WENDY L</u>						2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [BDTX]									all app	onship of Reporting Pe Il applicable) Director		10% Owner	
(Last)	`	irst) (MOND THERAP)	Middle)	S. INC.	3. Date of Earliest Transaction (Month/Day/Year) 12/15/2023										below	er (give title /)		Other (s	specify
ONE MAIN STREET, 14TH FLOOR					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02142														X	Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					tion 2A. Deemed Execution Date		i Date,	3. 4. Securitie Transaction Disposed Code (Instr. 5)		f, or Benef es Acquired (A) Of (D) (Instr. 3,		3) or 5. Ar 4 and Secu Bene Own		ount of ties cially I Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) o (D)	r Price	,	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 12/15/2				2023			A ⁽¹⁾		4,043	A	\$2.7	73(2)	3(2) 34,801			D			
		Tat	ble II -								osed of, o				Owne	d			
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any			nsaction de (Instr. 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		unt		tive derivative sy Securities		0. Dwnership orm: birect (D) r Indirect) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	de V (A) (D)			Date Exercis	able	Expiration Title		of Shares						

Explanation of Responses:

- 1. These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer
- $2. The price reported in Column \ 4 is based upon the closing market price of the Issuer's common stock on December \ 14,2023.$

/s/ Brent Hatzis-Schoch, 12/15/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.